Predictive and prognostic value of excision repair cross-complementing group 1 in patients with advanced gastric cancer.

ABSTRACT:

Background

To define the optimal chemotherapy regimen for each patient we therefore used tissue from patients to identify molecular prognostic or predictive biomarkers.

Methods

Endoscopic biopsy specimens from primary lesions and surgical specimens on a phase III trial in patients with unresectable advanced or recurrent gastric cancer treated with docetaxel with cisplatin plus S-1 (DCS) or cisplatin plus S-1 (CS), were collected. We measured the mRNA expression of ERCC1 and analyzed SNPs in GSTP1 and ERCC1.

Results

Low ERCC1 expression was associated with favorable prognosis for overall survival, OS by multivariable analysis (P = 0.001). There were significant interactions between the two treatment arms of DCS and CS, and ERCC1 mRNA expression. In patients with low ER

SUBMITTER: Yamada Y 

PROVIDER: S-EPMC11523942 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature